Sponsored
PRA International
By creating a parallel development pathway between global and China drug development there is potential to decrease time to market in China by 5 years. Read More

Sponsored
PPD
Download a new white paper that discusses the use of adaptive trial design in oncology to advance oncology research. Read More

Sponsored
Drug Development Strategies in China
Pharma and biotech firms who are relative newcomers to the Chinese market aren't aware that the regulatory climate has changed dramatically in recent years. SFDA approval times for Clinical Trials Approvals have dropped to 7-9 months for small molecules. There are also opportunities in China for sponsors that have not yet completed Phase II trials to create a parallel approval strategy. Even without final details (like final dosing) it’s possible to file a CTA for Phase III based on the most current early phase results. This parallel submission strategy can shave several months off the final approval time in China.
Read More

Sponsored
Covance(Xcellerate)
A lot of CROs offer databases. But only Covance offers Xcellerate^®, a more strategic approach to Clinical Trial Optimization ^®. Read More